الفهرس | Only 14 pages are availabe for public view |
Abstract S UMMARY dult acute lymphoblastic leukemia (ALL) accounts for approximately 15% to 20% of all adult acute leukemias. Overall, adults with ALL have a 60% to 80% chance or more of attaining first complete remission (CR1) using combination chemotherapy. However, many patients eventually relapse, particularly those with high-risk features such as age at diagnosis more than 35 years; white blood cell (WBC) count at diagnosis in excess of 30×109 /L (30 000/uL); non–T-cell phenotype; poor-risk cytogenetic abnormalities such as Philadelphia chromosome (Ph) positivity, t(4;11), or t(1;19); L2 or L3 phenotype; or failure to attain CR by ADAM28 is a member of the ADAM (a disintegrin and metalloproteinase) gene family and consists of two isoforms, prototype membrane-type form and short secreted form. The metalloproteinase domain of ADAM28 has the zinc binding consensus sequence, and ADAM28 exhibits catalytic activity to a few substrates such as insulin-like growth factor binding protein-3. There was high statistically significant difference between the studied groups as regards BMi There was high statistically significant difference between the studied groups as regard WBCs, Plts, blast and ESR and statistically significant difference as regard Hb. According to Cytogenetic risk category there were 4 (13.3%) favorable, 18 (60%) intermediate and 8 (26.7%) unfavorable. A Summary 77 There was high statistically significant difference between the studied groups as regard ADAM-28m and ADAM-28s. According to MRD there were 17 (56.7%) <0.1 and 13 (43.3%) >0.1 and there were 6 who died. There was significant correlation between ADAM-28 and MRD at follow-up. Based on our findings, we recommend for further studies on larger sample size and on large geographical scale to emphasize our conclusion. |